Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HMSC- A simple breast cancer screening device -- Ignore unavailable to you. Want to Upgrade?

To: (no name provided) who wrote (68)	3/3/1998 4:36:00 PM
From: Jason Loren Bauer	Read Replies (1) \| Respond to of 246

I'm not going to argue with you whether or not this product will succeed or not. Only time will tell. I'm not going to hold long-term so I don't really care whether or not this product ultimately succeeds. I will say however that some of the points you make in your post are not only outdated but just dead wrong. I'm counting on the HYPE to get me out of this play with a nice big profit ASAP. Here's the latest company press release that I think pumped the share price at the close. (The stock traded down to 11 3/4 until a late day buying surge brought the close to 12 1/2) Tuesday March 3, 3:09 pm Eastern Time Company Press Release SOURCE: HumanScan Inc. HumaScan Announces Consumer Education & Media Initiative for BreastAlert Differential Temperature Sensor and Free Video on Better Breast Health Jill Eikenberry begins national educational campaign including network television and exclusive NY appearance free of charge to the public CRANFORD, N.J. March 3 /PRNewswire/ -- HumaScan(R) Inc. (Nasdaq: HMSC - news), manufacturer of the BreastAlert(TM) Differential Temperature Sensor, today announced the beginning of its consumer education and media initiative with a presentation Wednesday, March 4, 1998, 6-8:30 pm, of ''How I Survived Breast Cancer,'' featuring Jill Eikenberry and Michael Tucker, Grand Hyatt Hotel, N.Y. Free videos on the importance of early detection are now available to the public by calling 1/888/HUMASCAN (486-2722.) Free tickets for the NY/Hyatt are available by calling 1-800-752-5588. As part of the consumer program to raise awareness on the importance of early detection of breast disease, HumaScan Inc. announced that Ms. Eikenberry is scheduled to appear March 5, 1998 on Good Morning America, as well as a series of nationally syndicated television and radio shows and a satellite broadcast which features BreastAlert and its role in ongoing breast monitoring programs. Additional appearances are scheduled in the coming days for Good Day New York, Geraldo, Bloomberg Business Television and Radio, Fox News, and Entertainment Weekly Radio. ''These appearances provide the ideal forum for women and their families to learn about BreastAlert, especially women under age 50 whose tumors can actually double in size in less than 80 days,'' said Donald Brounstein, president and chief executive officer of HumaScan Inc. BreastAlert is a non-invasive, easy to use, low cost adjunctive device to be used by gynecologists, primary care physicians, and other medical specialists as part of a breast disease monitoring program. In their New York presentation, which is available at no charge to the public, Ms. Eikenberry and her actor-husband, Michael Tucker, will discuss the changes to their lives during every aspect of Jill's battle with the disease. Following their program, members of the audience will be given the opportunity to ask questions of Ms. Eikenberry and Mr. Tucker and may direct inquiries to panel of leading clinicians and breast cancer experts representing Mount Sinai Medical Center in New York and Saint Barnabas Health Care System in New Jersey. Ms. Eikenberry is a breast cancer survivor who was diagnosed with the disease as she was beginning her stint on the long running television hit show, L.A. Law. Since undergoing successful treatment, she and her husband have dedicated themselves to a personal campaign of educating women about the need for better breast health. ''We want to help women nationwide learn the value of an ongoing breast monitoring program that includes clinical and breast self-exams as well as mammography, when indicated. Our message is important: 'The sooner you know, the better your chances,''' Ms. Eikenberry said. To obtain a free video about better breast health and early detection or for additional information on the BreastAlert( Differential Temperature Sensor, call toll free 1-888-HUMASCAN (486-2722) or visit on-line at www.humascan.com. Headquartered in Cranford, N.J., HumaScan Inc. is a development-stage company that focuses on easy-to-use, low-cost products and devices that assist physicians and specialists in the diagnosis and early detection of disease. This release contains forward-looking information including statements regarding the positive impact that this adjunctive product may have in assisting physicians in early detection of breast disease in women of all ages. Additional information on factors that could potentially affect the company's financial results may be found in the HumaScan Inc. filings with the Security and Exchange Commission. To receive additional information on HumaScan Inc., via fax, at no charge, dial 1-800-PRO-INFO and enter code HMSC.

To: (no name provided) who wrote (68)	3/3/1998 7:38:00 PM
From: FCC	Read Replies (3) \| Respond to of 246

The timing of your short is off. The stock will go through a period of profit taking but when? Here is the problems with your thoughts: 1. The reason that the product is not reimbursed at this time is because it had come to the market first. A OB-GYN friend of mine told me this fact. By the way Traveller's insurance comp. owns a stake in HMSC. 2.This product was never meant to replace mammograms, but to supplement them. This technology is more sensitive than mammos, and palpation of the breast by the doctor. This product is meant to be the earliest detection device for breast cancer, is they find a developing tumor the pt has a greater chance for survival. 3. The product cost only $40. Very inexpensive as compared to other tests. The doctors are charged $25 and make a small profit. 4. Any doctor who doesnt offer this test,even if it doesn't work for all patients will one day get a letter from the lawyers office wondering why their client was not given the opportunity to possibly catch the malignancy at an earlier reversible stage. 5. Patient has nothing to lose, to try a painless, radiation less, inexpensive, speedy test. The time that the women must wait to here results from mammos seems like an eternity. 6. No one knows how well this product works, that's why they are doing the clinical trials. They have made changes in the product before shipping. The reason for the delay was that the product gave a false reading if it was shipped to very warm climate. That has all been rectified. This is a very emotional area. We are dealing with potential blockbuster diagnostic tool. Vivus made a lot of money for the people timed the buys and sells correctly.By the way they can't keep the product on the shelf, it sells out of the box. There are more women that need this breast alert, than men who need vivus' help. GOOD LUCK TO THE LONGS!!!!!!